12:00 AM
 | 
Oct 15, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Canagliflozin: Phase III data

The double-blind, international Phase III DIA3010 trial in 714 Type II diabetics aged 55-80 with inadequate glycemic control showed that once-daily 100 and 300 mg oral canagliflozin each met the primary endpoint of reducing HbA1c from baseline to week 26 vs. placebo (0.6% and 0.73%, respectively vs. 0.03%, p<0.001 for both). On secondary endpoints, low- and high-dose canagliflozin led to significantly greater reductions in FPG (1 and 1.1 mmol/L, respectively, vs. a gain of 0.04 mmol/L, p<0.001 for...

Read the full 367 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >